Free Newsletter
Quaid sues Baxter over Heparin overdose
Are drug makers responsible for a hospital's medical error? That's what actor Dennis Quaid and his wife are alleging in a lawsuit over the blood thinner given to their newborn twins last month. The babies received 1,000 times the proper dose of Heparin, made by Baxter Healthcare.
At issue is the product label and design. The label on the 10-unit vial of Heparin is very similar to the label on the 10,000-unit strength. They're both blue, and the vials are similarly sized.
The couple is seeking only $50,000, saying that the suit is not about money, but about preventing the same overdose in other children. Last year, three Indiana children died after a healthcare worker gave them a similar overdose. Though Heparin, a generic, is made by seven different companies, it was Baxter's product involved in the Indiana overdose as well.
- read this BBC NEWS report
- get more details from the Chicago Sun-Times
Related Articles:
Heparin overdose at Cedars-Sinai. Report
Third baby dies at IN hospital. Report
Comments
By Anonymous | Posted 2:43pm | February 19, 2008
It sounds as though the Quaid family is doing what the hospitals, Baxter and the FDA have failed to accomplish...examine the issue. This is not about the money, it's about preventing what can be prevented. Human error is problematic and we need to have practices in place that help to address this and reduce the risk.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: